Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 554

1.

Unmet Needs in Appendiceal Neuroendocrine Neoplasms.

Toumpanakis C, Fazio N, Tiensuu Janson E, Hörsch D, Pascher A, Reed N, O'Toole D, Nieveen van Dijkum E, Partelli S, Rinke A, Kos-Kudla B, Costa F, Pape UF, Grozinsky-Glasberg S, Scoazec JY; ENETS 2016 Munich Advisory Board Participants.

Neuroendocrinology. 2018 Sep 20. doi: 10.1159/000493894. [Epub ahead of print]

PMID:
30235454
2.

Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?

Prud'homme C, Deschamps F, Allorant A, Massard C, Hollebecque A, Yevich S, Ngo-Camus M, Gravel G, Nicotra C, Michiels S, Scoazec JY, Lacroix L, Solary E, Soria JC, De Baere T, Tselikas L.

Eur J Cancer. 2018 Sep 14;103:108-119. doi: 10.1016/j.ejca.2018.08.003. [Epub ahead of print]

PMID:
30223224
3.

Influence of tumor-associated macrophages and HLA class I expression according to HPV status in head and neck cancer patients receiving chemo/bioradiotherapy.

Ou D, Adam J, Garberis I, Blanchard P, Nguyen F, Levy A, Casiraghi O, Gorphe P, Breuskin I, Janot F, Temam S, Scoazec JY, Deutsch E, Tao Y.

Radiother Oncol. 2018 Aug 29. pii: S0167-8140(18)33451-0. doi: 10.1016/j.radonc.2018.08.013. [Epub ahead of print]

PMID:
30172455
4.

A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, Fernandez-Cuesta L, Klöppel G, McCluggage WG, Moch H, Ohgaki H, Rakha EA, Reed NS, Rous BA, Sasano H, Scarpa A, Scoazec JY, Travis WD, Tallini G, Trouillas J, van Krieken JH, Cree IA.

Mod Pathol. 2018 Aug 23. doi: 10.1038/s41379-018-0110-y. [Epub ahead of print]

PMID:
30140036
5.

Increased expression of the thyroid hormone nuclear receptor TRα1 characterizes intestinal tumors with high Wnt activity.

Uchuya-Castillo J, Aznar N, Frau C, Martinez P, Le Nevé C, Marisa L, Penalva LOF, Laurent-Puig P, Puisieux A, Scoazec JY, Samarut J, Ansieau S, Plateroti M.

Oncotarget. 2018 Jul 24;9(57):30979-30996. doi: 10.18632/oncotarget.25741. eCollection 2018 Jul 24.

6.

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.

Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S, Hollebecque A, Scoazec JY, Marabelle A, Massard C, Soria JC, Robert C, Paragios N, Deutsch E, Ferté C.

Lancet Oncol. 2018 Sep;19(9):1180-1191. doi: 10.1016/S1470-2045(18)30413-3. Epub 2018 Aug 14.

PMID:
30120041
7.

Added Value of Whole-Exome and Transcriptome Sequencing for Clinical Molecular Screenings of Advanced Cancer Patients With Solid Tumors.

Koeppel F, Bobard A, Lefebvre C, Pedrero M, Deloger M, Boursin Y, Richon C, Chen-Min-Tao R, Robert G, Meurice G, Rouleau E, Michiels S, Massard C, Scoazec JY, Solary E, Soria JC, André F, Lacroix L.

Cancer J. 2018 Jul/Aug;24(4):153-162. doi: 10.1097/PPO.0000000000000322.

PMID:
30119077
8.

Prevalence, Risk Factors, and Impact of Donor-Specific Alloantibodies After Adult Liver Transplantation.

Vandevoorde K, Ducreux S, Bosch A, Guillaud O, Hervieu V, Chambon-Augoyard C, Poinsot D, André P, Scoazec JY, Robinson P, Boillot O, Dubois V, Dumortier J.

Liver Transpl. 2018 Aug;24(8):1091-1100. doi: 10.1002/lt.25177.

PMID:
29665189
9.

Multimodal Management of Locally Advanced Neuroendocrine Cervical Carcinoma: A Single Institution Experience.

Castelnau-Marchand P, Pautier P, Genestie C, Leary A, Bentivegna E, Gouy S, Scoazec JY, Morice P, Haie-Meder C, Chargari C.

Int J Gynecol Cancer. 2018 Jun;28(5):1013-1019. doi: 10.1097/IGC.0000000000001242.

PMID:
29595759
10.

Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors: A National Study from the French Group of Endocrine Tumors (GTE).

Rault-Petit B, Do Cao C, Guyétant S, Guimbaud R, Rohmer V, Julié C, Baudin E, Goichot B, Coriat R, Tabarin A, Ramos J, Goudet P, Hervieu V, Scoazec JY, Walter T.

Ann Surg. 2018 Mar 19. doi: 10.1097/SLA.0000000000002736. [Epub ahead of print]

PMID:
29557879
11.

Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.

Cabel L, Fuerea A, Lacroix L, Baldini C, Martin P, Hollebecque A, Postel-Vinay S, Varga A, Balheda R, Gazzah A, Michot JM, Marabelle A, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, Scoazec JY, Ammari S, André F, Soria JC, Massard C, Verlingue L.

Oncotarget. 2018 Jan 12;9(11):9741-9750. doi: 10.18632/oncotarget.24188. eCollection 2018 Feb 9.

12.

Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver.

Schmitt C, Lenglet H, Yu A, Delaby C, Benecke A, Lefebvre T, Letteron P, Paradis V, Wahlin S, Sandberg S, Harper P, Sardh E, Sandvik AK, Hov JR, Aarsand AK, Chiche L, Bazille C, Scoazec JY, To-Figueras J, Carrascal M, Abian J, Mirmiran A, Karim Z, Deybach JC, Puy H, Peoc'h K, Manceau H, Gouya L.

J Intern Med. 2018 Jul;284(1):78-91. doi: 10.1111/joim.12750. Epub 2018 Mar 26.

PMID:
29498764
13.

Corrigendum to "Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial" [Eur J Cancer 87 (2017) 122-130].

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A.

Eur J Cancer. 2018 Apr;93:156-157. doi: 10.1016/j.ejca.2018.01.077. Epub 2018 Feb 14. No abstract available.

PMID:
29454743
14.

Daily Biopsy Diagnosis in Surgical Pathology: Concordance Between Light Microscopy and Whole-Slide Imaging in Real-Life Conditions.

Villa I, Mathieu MC, Bosq J, Auperin A, Pomerol JF, Lacroix-Triki M, Scoazec JY, Dartigues P.

Am J Clin Pathol. 2018 Mar 7;149(4):344-351. doi: 10.1093/ajcp/aqx161.

PMID:
29452345
15.

Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.

Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C.

Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3.

PMID:
29413684
16.

Tumour spheres with inverted polarity drive the formation of peritoneal metastases in patients with hypermethylated colorectal carcinomas.

Zajac O, Raingeaud J, Libanje F, Lefebvre C, Sabino D, Martins I, Roy P, Benatar C, Canet-Jourdan C, Azorin P, Polrot M, Gonin P, Benbarche S, Souquere S, Pierron G, Nowak D, Bigot L, Ducreux M, Malka D, Lobry C, Scoazec JY, Eveno C, Pocard M, Perfettini JL, Elias D, Dartigues P, Goéré D, Jaulin F.

Nat Cell Biol. 2018 Mar;20(3):296-306. doi: 10.1038/s41556-017-0027-6. Epub 2018 Feb 5.

PMID:
29403038
17.

Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?

Pradère P, Boutros C, Scoazec JY, Dorfmüller P, Leroy-Ladurie F, Boulate D, Le Pavec J, Robert C.

Eur J Cancer. 2018 Apr;93:144-146. doi: 10.1016/j.ejca.2017.12.013. Epub 2018 Feb 3. No abstract available.

PMID:
29402507
18.

Arterial thrombosis and anti-PD-1 blockade.

Boutros C, Scoazec JY, Mateus C, Routier E, Roy S, Robert C.

Eur J Cancer. 2018 Mar;91:164-166. doi: 10.1016/j.ejca.2017.11.018. Epub 2017 Dec 27. No abstract available.

PMID:
29289455
19.

Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.

Delahousse J, Verlingue L, Broutin S, Legoupil C, Touat M, Doucet L, Ammari S, Lacroix L, Ducreux M, Scoazec JY, Malka D, Paci A, Hollebecque A.

Eur J Cancer. 2018 Feb;90:83-91. doi: 10.1016/j.ejca.2017.11.024. Epub 2018 Jan 4.

PMID:
29274619
20.

Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.

Walter T, Malka D, Hentic O, Lombard-Bohas C, Le Malicot K, Smith D, Ferru A, Assenat E, Cadiot G, Lievre A, Kurtz JE, Dahan L, Dubreuil O, Hautefeuille V, Lepere C, Gangloff A, Elhajbi F, Coriat R, Roquin G, Bouarioua N, Granger V, Scoazec JY, Lepage C.

Dig Liver Dis. 2018 Feb;50(2):195-198. doi: 10.1016/j.dld.2017.11.020. Epub 2017 Dec 6.

PMID:
29258812
21.

Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma.

Rigaud C, Abbou S, Minard-Colin V, Geoerger B, Scoazec JY, Vassal G, Jaff N, Heuberger L, Valteau-Couanet D, Brugieres L.

Pediatr Blood Cancer. 2018 Apr;65(4). doi: 10.1002/pbc.26902. Epub 2017 Nov 28. No abstract available.

PMID:
29193772
22.

[Classification of pancreatic neuroendocrine tumours: Changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future].

Scoazec JY, Couvelard A; Réseau TENpath.

Ann Pathol. 2017 Dec;37(6):444-456. doi: 10.1016/j.annpat.2017.10.003. Epub 2017 Nov 21. French.

PMID:
29169836
23.

Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial.

Verlingue L, Malka D, Allorant A, Massard C, Ferté C, Lacroix L, Rouleau E, Auger N, Ngo M, Nicotra C, De Baere T, Tselikas L, Ba B, Michiels S, Scoazec JY, Boige V, Ducreux M, Soria JC, Hollebecque A.

Eur J Cancer. 2017 Dec;87:122-130. doi: 10.1016/j.ejca.2017.10.013. Epub 2017 Nov 14. Erratum in: Eur J Cancer. 2018 Feb 14;:.

PMID:
29145038
24.

Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma.

Ali AS, Grönberg M, Federspiel B, Scoazec JY, Hjortland GO, Grønbæk H, Ladekarl M, Langer SW, Welin S, Vestermark LW, Arola J, Österlund P, Knigge U, Sorbye H, Grimelius L, Janson ET.

PLoS One. 2017 Nov 7;12(11):e0187667. doi: 10.1371/journal.pone.0187667. eCollection 2017.

25.

Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy.

Ou D, Garberis I, Adam J, Blanchard P, Nguyen F, Levy A, Casiraghi O, Gorphe P, Breuskin I, Janot F, Temam S, Scoazec JY, Deutsch E, Tao Y.

Radiother Oncol. 2018 Jan;126(1):116-124. doi: 10.1016/j.radonc.2017.10.007. Epub 2017 Nov 1.

PMID:
29079308
26.

Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells.

Bollard J, Patte C, Massoma P, Goddard I, Gadot N, Benslama N, Hervieu V, Ferraro-Peyret C, Cordier-Bussat M, Scoazec JY, Roche C, Walter T, Vercherat C.

Mol Cancer Ther. 2018 Jan;17(1):60-72. doi: 10.1158/1535-7163.MCT-17-0325. Epub 2017 Oct 19.

PMID:
29051320
27.

Ovarian Cancer: A Heterogeneous Disease.

Kossaï M, Leary A, Scoazec JY, Genestie C.

Pathobiology. 2018;85(1-2):41-49. doi: 10.1159/000479006. Epub 2017 Oct 12.

PMID:
29020678
28.

Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities.

Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, Boselli L, Kamsukom N, Mateus C, Charrier M, Cassard L, Planchard D, Ribrag V, Fizazi K, Loriot Y, Lepage P, Scoazec JY, Robert C, Carbonnel F, Chaput N.

J Crohns Colitis. 2017 Oct 1;11(10):1238-1246. doi: 10.1093/ecco-jcc/jjx081.

PMID:
28967957
29.

Clinical relevance of tumor infiltrating lymphocytes, PD-L1 expression and correlation with HPV/p16 in head and neck cancer treated with bio- or chemo-radiotherapy.

Ou D, Adam J, Garberis I, Blanchard P, Nguyen F, Levy A, Casiraghi O, Gorphe P, Breuskin I, Janot F, Temam S, Scoazec JY, Deutsch E, Tao Y.

Oncoimmunology. 2017 Jul 5;6(9):e1341030. doi: 10.1080/2162402X.2017.1341030. eCollection 2017.

30.

Are we reproducible in measurement of NET liver metastasis?

Moalla S, Arfi Rouche J, Foulon S, Caramella C, Ternes N, Planchard D, Goere D, Ducreux M, Scoazec JY, Deschamps F, Dromain C, Baudin E.

Dig Liver Dis. 2017 Oct;49(10):1121-1127. doi: 10.1016/j.dld.2017.05.015. Epub 2017 Jun 28.

PMID:
28844707
31.

Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter Study.

Marciello F, Mercier O, Ferolla P, Scoazec JY, Filosso PL, Chapelier A, Guggino G, Monaco R, Grimaldi F, Pizzolitto S, Guigay J, de Latour BR, Giuffrida D, Longchampt E, de Montpreville VT, Fadel E, Colao A, Planchard D, Papotti M, Faggiano A, Baudin E.

Neuroendocrinology. 2018;106(3):264-273. doi: 10.1159/000480015. Epub 2017 Aug 17.

PMID:
28813709
32.

Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study.

Lecomte P, Binquet C, Le Bras M, Tabarin A, Cardot-Bauters C, Borson-Chazot F, Lombard-Bohas C, Baudin E, Delemer B, Klein M, Vergès B, Aparicio T, Cosson E, Beckers A, Caron P, Chabre O, Chanson P, Du Boullay H, Guilhem I, Niccoli P, Rohmer V, Guigay J, Vulpoi C, Scoazec JY, Goudet P.

World J Surg. 2018 Jan;42(1):143-152. doi: 10.1007/s00268-017-4135-z.

PMID:
28785839
33.

Deleterious impact of C3d-binding donor-specific anti-HLA antibodies after pediatric liver transplantation.

Couchonnal E, Rivet C, Ducreux S, Dumortier J, Bosch A, Boillot O, Collardeau-Frachon S, Dubois R, Hervieu V, André P, Scoazec JY, Lachaux A, Dubois V, Guillaud O.

Transpl Immunol. 2017 Dec;45:8-14. doi: 10.1016/j.trim.2017.08.001. Epub 2017 Aug 3.

PMID:
28782692
34.

Predictive and prognostic value of CT based radiomics signature in locally advanced head and neck cancers patients treated with concurrent chemoradiotherapy or bioradiotherapy and its added value to Human Papillomavirus status.

Ou D, Blanchard P, Rosellini S, Levy A, Nguyen F, Leijenaar RTH, Garberis I, Gorphe P, Bidault F, Ferté C, Robert C, Casiraghi O, Scoazec JY, Lambin P, Temam S, Deutsch E, Tao Y.

Oral Oncol. 2017 Aug;71:150-155. doi: 10.1016/j.oraloncology.2017.06.015. Epub 2017 Jun 26.

PMID:
28688683
35.

Gastrointestinal stromal tumors (GIST) presenting in the liver: Diagnostic, prognostic and therapeutic issues.

Joyon N, Dumortier J, Aline-Fardin A, Caramella C, Valette PJ, Blay JY, Scoazec JY, Dartigues P.

Clin Res Hepatol Gastroenterol. 2018 Apr;42(2):e23-e28. doi: 10.1016/j.clinre.2017.05.010. Epub 2017 Jun 20.

PMID:
28645742
36.

Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma.

Jouenne F, Chauvot de Beauchene I, Bollaert E, Avril MF, Caron O, Ingster O, Lecesne A, Benusiglio P, Terrier P, Caumette V, Pissaloux D, de la Fouchardière A, Cabaret O, N'Diaye B, Velghe A, Bougeard G, Mann GJ, Koscielny S, Barrett JH, Harland M, Newton-Bishop J, Gruis N, Van Doorn R, Gauthier-Villars M, Pierron G, Stoppa-Lyonnet D, Coupier I, Guimbaud R, Delnatte C, Scoazec JY, Eggermont AM, Feunteun J, Tchertanov L, Demoulin JB, Frebourg T, Bressac-de Paillerets B.

J Med Genet. 2017 Sep;54(9):607-612. doi: 10.1136/jmedgenet-2016-104402. Epub 2017 Jun 7.

37.

Portal Vein Thrombosis and Nephrotic Syndrome After Liver Transplant.

Dumortier J, Sicard A, Guillaud O, Valette PJ, Scoazec JY, Boillot O.

Exp Clin Transplant. 2017 Jun 5. doi: 10.6002/ect.2016.0259. [Epub ahead of print]

38.

Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.

Walter T, Tougeron D, Baudin E, Le Malicot K, Lecomte T, Malka D, Hentic O, Manfredi S, Bonnet I, Guimbaud R, Coriat R, Lepère C, Desauw C, Thirot-Bidault A, Dahan L, Roquin G, Aparicio T, Legoux JL, Lombard-Bohas C, Scoazec JY, Lepage C, Cadiot G; CEPD investigators.

Eur J Cancer. 2017 Jul;79:158-165. doi: 10.1016/j.ejca.2017.04.009. Epub 2017 May 11.

PMID:
28501762
39.

Methylprednisolone liver toxicity: A new case and a French regional pharmacovigilance survey.

Dumortier J, Cottin J, Lavie C, Guillaud O, Hervieu V, Chambon-Augoyard C, Scoazec JY, Vukusic S, Vial T.

Clin Res Hepatol Gastroenterol. 2017 Sep;41(4):497-501. doi: 10.1016/j.clinre.2017.03.008. Epub 2017 Apr 21.

PMID:
28438569
40.

mTOR inhibitors activate PERK signaling and favor viability of gastrointestinal neuroendocrine cell lines.

Freis P, Bollard J, Lebeau J, Massoma P, Fauvre J, Vercherat C, Walter T, Manié S, Roche C, Scoazec JY, Ferraro-Peyret C.

Oncotarget. 2017 Mar 28;8(13):20974-20987. doi: 10.18632/oncotarget.15469.

41.

Hepatocyte nuclear factor 1α suppresses steatosis-associated liver cancer by inhibiting PPARγ transcription.

Patitucci C, Couchy G, Bagattin A, Cañeque T, de Reyniès A, Scoazec JY, Rodriguez R, Pontoglio M, Zucman-Rossi J, Pende M, Panasyuk G.

J Clin Invest. 2017 May 1;127(5):1873-1888. doi: 10.1172/JCI90327. Epub 2017 Apr 10.

42.

ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Biochemical Markers.

Oberg K, Couvelard A, Delle Fave G, Gross D, Grossman A, Jensen RT, Pape UF, Perren A, Rindi G, Ruszniewski P, Scoazec JY, Welin S, Wiedenmann B, Ferone D; Antibes Consensus Conference participants.

Neuroendocrinology. 2017;105(3):201-211. doi: 10.1159/000472254. Epub 2017 Apr 8. No abstract available.

PMID:
28391265
43.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC.

Cancer Discov. 2017 Jun;7(6):586-595. doi: 10.1158/2159-8290.CD-16-1396. Epub 2017 Apr 1.

44.

Survival and prognostic factors after adjuvant 131iodine-labeled lipiodol for hepatocellular carcinoma: a retrospective analysis of 106 patients over 20 years.

Olesinski J, Mithieux F, Guillaud O, Hilleret MN, Lombard-Bohas C, Henry L, Boillot O, Walter T, Partensky C, Paliard P, Valette PJ, Vuillez JP, Borson-Chazot F, Scoazec JY, Dumortier J.

Ann Nucl Med. 2017 Jun;31(5):379-389. doi: 10.1007/s12149-017-1165-4. Epub 2017 Mar 24.

PMID:
28342103
45.

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.

Lepage C, Dahan L, Bouarioua N, Toumpanakis C, Legoux JL, Le Malicot K, Guimbaud R, Smith D, Tougeron D, Lievre A, Cadiot G, Di Fiore F, Bouhier-Leporrier K, Hentic O, Faroux R, Pavel M, Borbath I, Valle JW, Rinke A, Scoazec JY, Ducreux M, Walter T.

Dig Liver Dis. 2017 May;49(5):568-571. doi: 10.1016/j.dld.2017.02.004. Epub 2017 Mar 11.

PMID:
28292641
46.

[Gastric adenoma of pyloric type associated with familial adenomatous polyposis: A rare histological type not to be overlooked].

Didier J, Dartigues P, Soufan R, Malka D, Burtin P, Scoazec JY.

Ann Pathol. 2017 Apr;37(2):175-181. doi: 10.1016/j.annpat.2017.01.003. Epub 2017 Mar 9. French.

PMID:
28285810
47.

Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.

Sullivan I, Le Teuff G, Guigay J, Caramella C, Berdelou A, Leboulleux S, Déandréis D, Hadoux J, Ducreux M, Duvillard P, Adam J, Scoazec JY, Baudin E, Planchard D.

Eur J Cancer. 2017 Apr;75:259-267. doi: 10.1016/j.ejca.2016.11.034. Epub 2017 Feb 27.

PMID:
28242503
48.

ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours.

Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, Nieveen van Dijkum EJM, Pape UF, Pascher A, Ramage J, Reed N, Ruszniewski P, Scoazec JY, Toumpanakis C, Kianmanesh R, Falconi M; Antibes Consensus Conference participants.

Neuroendocrinology. 2017;105(3):255-265. doi: 10.1159/000464292. Epub 2017 Feb 25. No abstract available.

PMID:
28237989
49.

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification.

Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, Gorbounova V, Gross D, Grossma A, Jense RT, Kulke M, Oeberg K, Rindi G, Sorbye H, Welin S; Antibes Consensus Conference participants.

Neuroendocrinology. 2017;105(3):196-200. doi: 10.1159/000457956. Epub 2017 Feb 11. No abstract available.

50.

Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).

Roquin G, Baudin E, Lombard-Bohas C, Cadiot G, Dominguez S, Guimbaud R, Niccoli P, Legoux JL, Mitry E, Rohmer V, Ruszniewski P, Walter T, Ducreux M, Couvelard A, Scoazec JY, Ramond-Roquin A, Caroli-Bosc FX, Hentic O.

Neuroendocrinology. 2018;106(1):38-46. doi: 10.1159/000457955. Epub 2017 Feb 3.

Supplemental Content

Loading ...
Support Center